Cochlear had a softer start to its half yearly result, with sales of A$1.1 billion down around 1%.
The bigger issue for investors was underlying net profit, which appears to have been the key driver behind the 16% drawdown and the broader selling pressure.
Net cash remained solid at A$173 million, although it was down…
Healthcare Stocks
A Premium Multiple Leaves No Room for “Good”
Pro Medicus fell 16% despite what, on the surface, looked like an exceptional half yearly result. A lot of investors will be asking the obvious question: how can a company print a strong result and still get sold off that hard?
The core principle here is asset pricing.…
Rhythm Biosciences Starts ColoSTAT Pilot, Revenue Still Unclear
Rhythm Biosciences (ASX: RHY) just hit a milestone the market has been waiting for, enrolling its first doctor in the ColoSTAT Access Program, a small pilot program that will test its blood-based bowel cancer screening product in real clinical settings for the first time. The share price…
In a bombshell 4pm announcement, investors learned that CSL CEO Paul McKenzie was departing the company effective that very afternoon following a tenure of nearly 3 years. It was clear that something had to give, but this is still a shock as it occurred a day before company results and resulted in McKenzies' tenure lasting…
Imagion Biosystems (ASX:IBX) just made a IND submission. This is a big deal for the company, and we thought it would be the perfect time to explain to investors just what this means.
What are the Best ASX Stocks to invest in right now?
Check our buy/sell tips
[sg_popup id="23914" event="click"]
[/sg_popup]
Here's what you need to know about…
Immutep (ASX: IMM) has pulled back roughly 22 per cent from its recent 52-week high near A$0.46, settling around A$0.36 this week. The selloff comes despite no change to the company's clinical outlook and follows a strong rally that began in early December after Immutep signed a landmark licensing deal with Dr Reddy's Laboratories.
What…
PYC Therapeutics (ASX:PYC) is currently in the Top 25 ASX healthcare stocks and is the 4th largest biotech, only trailing Telix, Mesoblast and Neuren. Clearly this is one worth looking into and this was before a capital raising that would be $650m and purportedly fund the company into next decade.
What are the Best ASX Life…
Island Pharmaceuticals jumps after FDA backs galidesivir pathway
Island Pharmaceuticals (ASX: ILA) surged as much as 23% to an intraday high of A$0.48 on Wednesday before settling at A$0.42, after delivering a dual catalyst that has significantly de-risked its lead drug program. The US Food and Drug Administration has confirmed the validity of the company's…
Neuren Pharmaceuticals: Is the 10% drop a buy signal?
Neuren Pharmaceuticals (ASX: NEU) dropped nearly 10% on Tuesday, falling to A$14.63 from a previous close of A$16.25. The sell-off came after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative trend vote on trofinetide, the company's Rett syndrome treatment…
ResMed data shows GLP-1 users use CPAP more
Is it time to buy ResMed (ASX: RMD)? Well, the company is having good momentum right now - it delivered another strong quarter, beating analyst expectations on both revenue and earnings. The stock currently trades around A$37.50 on the ASX. But the bigger story for investors is…
